The Mirmira Lab, together with investigators at Indiana University School of Medicine, published a new study in Cell Reports Medicine that investigates α-difluoromethylornithine (DFMO) as a potential therapeutic for type 1 diabetes. In a randomized controlled trial of 41 recent-onset type 1 diabetes subjects, DFMO was safe, well-tolerated, and preserved β cell function. The next milestone is to advance DFMO into a larger clinical trial. Read more about the study here.